EG225058 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid, an HDAC inhibitor, modulates Gm4832 indirectly by influencing chromatin remodeling. Alterations in histone acetylation patterns, induced by Vorinostat, lead to changes in Gm4832 expression and its downstream cellular functions within the epigenetic context. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR, an AMPK activator, indirectly influences Gm4832 by regulating cellular energy homeostasis. Activation of AMPK modulates downstream pathways, impacting Gm4832 expression and cellular functions associated with energy sensing and metabolism. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Gm4832 by affecting the mTOR signaling pathway. Suppression of mTOR activity leads to alterations in downstream signaling cascades, resulting in changes in Gm4832 expression and its associated cellular functions within the context of mTOR-regulated processes. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin, an HSP90 inhibitor, indirectly influences Gm4832 by targeting the heat shock protein 90 (HSP90). Inhibition of HSP90 by Geldanamycin results in altered protein folding and stability, impacting Gm4832 expression and its associated cellular functions within the context of chaperone-mediated regulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, indirectly modulates Gm4832 by affecting the MAPK pathway. Inhibition of MEK by PD98059 disrupts downstream signaling, leading to changes in Gm4832 expression and its associated cellular functions within the context of MAPK-regulated processes. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763, a GSK-3β inhibitor, indirectly influences Gm4832 by modulating the Wnt signaling pathway. Inhibition of GSK-3β by SB216763 leads to altered Wnt signaling, impacting Gm4832 expression and cellular functions associated with the Wnt pathway. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
C646, a p300/CBP inhibitor, indirectly modulates Gm4832 by targeting the histone acetyltransferases p300/CBP. Inhibition of p300/CBP by C646 leads to changes in histone acetylation patterns, influencing Gm4832 expression and its downstream cellular functions within the epigenetic context. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, indirectly influences Gm4832 by disrupting the PI3K/mTOR pathway. Suppression of PI3K and mTOR activities by PI-103 leads to changes in Gm4832 expression and its associated cellular functions within the context of PI3K/mTOR-regulated processes. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG, an HSP90 inhibitor, indirectly influences Gm4832 by targeting the heat shock protein 90 (HSP90). Inhibition of HSP90 by 17-AAG results in altered protein folding and stability, impacting Gm4832 expression and its associated cellular functions within the context of chaperone-mediated regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly modulates Gm4832 by affecting the p38 MAPK pathway. Inhibition of p38 MAPK by SB203580 disrupts downstream signaling, leading to changes in Gm4832 expression and its associated cellular functions within the context of MAPK-regulated processes. | ||||||